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AbstrAct 
Objective To explore the impact of weekly transcorneal 
electrical stimulation (TES) over a 6-month period as a 
treatment for retinitis pigmentosa (RP).
Methods and analysis A prospective open-label 
observational trial was carried out assessing weekly TES 
in participants with RP for a period of 6 months followed 
by observation for a further 6 months. Clinical examination 
and investigations were carried out at 3 monthly intervals 
for a total of 12 months. The primary outcome measure 
explored safety through a descriptive analysis of adverse 
effects with secondary outcome measures evaluating 
structural and functional efficacy.
results Seven male and seven female participants 
with RP aged 18–80 years were recruited. TES was well 
tolerated with no serious adverse events reported. Two 
participants reported transient foreign body sensation 
and one participant had discomfort underneath the skin 
electrode. Following 6 months of TES, best-corrected visual 
acuity increased by 1.1±1.4 letters in the control arm and 
0.93±1.4 letters in the treated arm. Central microperimetry 
threshold sensitivity rose by 0.02±0.5 decibels (dB) 
and 0.37±0.4 dB and Goldmann visual field volume by 
0.16±0.09 steradians (sr) vs 0.22±0.12 sr for the control 
and treated eye, respectively. There was no statistical 
significance seen between eyes following the treatment or 
observation period.
conclusion This small open-label clinical trial showed 
that TES was safe and well tolerated in patients with RP. 
Visual function measurements at 6 months demonstrated 
no significant difference between the control and treated 
eyes. The results justify a larger clinical trial over a longer 
period of time in order to identify any treatment effect.
IntrOductIOn
Retinitis pigmentosa (RP) describes a group 
of genetically heterogeneous retinal dystro-
phies, typically characterised by a primary 
loss of rods with secondary cone involve-
ment. There remains no established therapy 
for RP and thus the condition frequently 
leads to substantial visual impairment in the 
majority of patients. One proposed strategy 
to halt or slow progressive photoreceptor 
loss is the administration of transcorneal 
electrical stimulation (TES). TES confers 
preservation of outer nuclear layer thickness 
and electroretinography function (ERG) in 
murine models of retinal degeneration after 
6 weeks of therapy.1 Similarly, retinal ganglion 
cell death following optic nerve transec-
tion can be significantly reduced following 
a single session of TES.2 These benefits are 
believed to result from the upregulation 
of specific neurotrophic factors.3 4 Several 
groups have demonstrated an increase in 
ciliary neurotrophic factor, fibroblast growth 
factor alpha and brain-derived neurotrophic 
factor following electrical stimulation.5–7 
Interestingly, participants receiving elec-
tronic subretinal implants have shown visual 
improvement in areas distant from the implant 
further suggesting that electrical stimulation 
may induce benefit through an amplification 
of neurotrophins.8 9 Further contribution 
may come from improved chorioretinal 
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Key messages
What is already known about this subject?
Transcorneal electrical stimulation (TES) induces 
photoreceptor preservation in murine models of retinal 
degeneration. A pilot study in eight human participants 
undergoing weekly TES for 6 weeks showed significant 
improvements in their kinetic perimetry and scotopic 
electroretinography.
What are the new findings?
This study provides further evidence of the safety 
profile of TES with no serious adverse effects noted. 
The most common side effect was transient self-
resolving foreign body sensation. Psychophysics and 
structural measures of optical coherence tomography 
and fundus autofluorescence did not reveal any 
significant change when comparing the control with 
the treated eye.
How might these results change the focus of 
research or clinical practice?
The growing evidence supporting the safety of TES 
justifies a larger clinical trial of longer duration. 
Participants should ideally show demonstrable 
deterioration in the control eye to identify any potential 
treatment effect.
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Table 1 Demographics of all participants
Participant (MEH GC) Age Sex Mutation OCT
P1 (GC31769) 36 F * Mild ERM
P2 (GC3326) 56 M USH2A Staphyloma
P3 78 M * Mild ERM
P4 (GC31266) 26 F PRPH2
P5 (GC29402) 49 F *
P6 (GC29304) 25 M *
P7 37 M RPGR Mild ERM
P8 66 F PRP31
P9 68 F *
P10 18 M RPGR
P11 56 F USH2A
P12 71 M IMPG2
P13 39 M * Mild ERM
P14 42 F * Mild ERM
Seven patients had positive next-generation sequencing for 
recognised mutational variants (*not identified). 
ERM, epiretinal membrane
circulation, which has been shown to increase following 
TES in normal participants,10 although it is unclear 
whether this is in addition or secondary to neurotrophic 
upregulation. 
TES has been reported to improve visual function 
in humans with retinal artery occlusion, non-arteritic 
ischaemic optic neuropathy and traumatic optic neurop-
athy,11–13 as well as inherited retinal dystrophies, such 
as Best vitelliform macular dystrophy.14 In RP, an initial 
pilot study assessing six sessions of weekly TES in eight 
participants showed significant improvements in kinetic 
perimetry and scotopic ERG function.15 However, a subse-
quent follow-up study did not reproduce psychophysical 
improvements but revealed gains in the photopic b-wave 
amplitude.16 Given its low-risk profile and ease of appli-
cation, TES remains an attractive potential therapeutic 
option. Here, we report the results of the Transcorneal 
Electrical Stimulation for the treatment of retinitis 
pigmentosa Open Label multicentre UK study exploring 
primarily the safety and secondarily the efficacy of TES 
in participants with RP recruited for a 12-month period 
commencing with 6 months of weekly TES.
subjects And MetHOds
Fourteen participants with rod-cone dystrophy were 
recruited into an open-label interventional trial from the 
retinal genetics clinics at the Oxford Eye Hospital and 
Moorfields Eye Hospital. Clinical diagnosis of RP, defined 
in this study as an inherited retinal disease of rod-cone 
dystrophy, was through history, posterior segment exam-
ination, fundus autofluorescence (AF), optical coherence 
tomography and, in most cases, full-field electroretinog-
raphy. Seven participants had recognised mutational 
variants on next-generation sequencing, as illustrated in 
table 1. In addition to a diagnosis of RP, inclusion criteria 
were 18–80 years of age, a visual acuity >0.02 (Snellen 
decimal) and sufficient motor skills to apply the device 
independently. Exclusion criteria were the presence of 
diabetic retinopathy, previous retinal vascular occlusion, 
glaucoma, previous retinal detachment, previous silicone 
oil tamponade, macular oedema, corneal disease, neovas-
cularisation of any origin and female participants who 
were pregnant or planning pregnancy during the course 
of the study. In addition, simultaneous participation in 
another interventional study, and some forms of mental 
illness, which might interfere with study participation, 
were exclusion criteria.
Following recruitment, participants were assessed at a 
baseline visit and underwent phosphene threshold deter-
mination and a first session of TES. Follow-up assessments 
were three monthly through one total year of participa-
tion. TES was administered weekly under the supervision 
of a trained member of the research team for 30 min for 
the first 6 months over a minimum of 24 sessions of TES. 
A discussion regarding any adverse effects experienced 
took place each week prior to TES. Participants were 
then observed for a further 6 months without any TES at 
3 monthly intervals.
Data were recorded in the clinical notes and the Case 
Report Form. Data monitoring was provided by an inde-
pendent Contract Research Organisation, STZ Eyetrial, 
based at the University Hospital Tuebingen and was 
conducted within the stipulations of the International 
Conference on Harmonisation (Geneva, Switzerland). 
The study was conducted according to the tenets of the 
Declaration of Helsinki (2008) and Good Clinical Prac-
tice. All participants gave informed consent prior to 
enrolment. Public trial registration was through  clinical-
trials. gov (NCT01847365).
Visual function was measured at 3 monthly intervals 
using ETDRS best-corrected visual acuity (BCVA) at 4 m, 
Goldmann visual field analysis and MAIA microperim-
etry (MP) (Centervue, Padova, Italy). MP was performed 
prior to dilation, following 20 min of dark adaptation. 
The MAIA combines a scanning laser ophthalmoscope 
with perimetry—a Goldmann size III (0.7 degree diam-
eter) target was projected onto the ocular fundus via an 
artificial entrance pupil measuring 2 mm as previously 
described.17 Average threshold sensitivities were deter-
mined for the central 10 degrees (10–2 test) of the field 
of vision. Test accuracy was ≥85% for each test.
Retinal structure was assessed using Heidelberg Spec-
tralis spectral domain optical coherence tomography 
(OCT) in accordance with the manufacturer’s protocols. 
Fundus AF imaging was performed with a Heidelberg 
Spectralis OCT-confocal scanning laser ophthalmoscopy 
machine with the BluePeak blue laser AF module (Heidel-
berg Engineering GmbH, Heidelberg, Germany).
electrical stimulation
TES was administered using sterile single-use DTL elec-
trodes (OkuEl) positioned onto a rigid semicircular 
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Figure 1 Flow chart illustrating the recruitment and progress of participants. The most frequent reason for exclusion was the 
presence of cystoid macular oedema (due to the independent variability in this clinical feature of RP, which would influence 
visual acuity readings). All participants completed the 6-month treatment period, although two withdrew during the observation 
period for personal reasons. TES, transcorneal electrical stimulation.
frame mounted onto the OkuSpex, a metallic specta-
cle-like frame (see online supplementary figure 1). 
The electrode was placed into the inferior fornix. The 
participant’s ipsilateral forehead was cleaned using 
70% isopropyl alcohol and electrode contact paste 
with a skin counter electrode placed over the area. 
Electrodes were attached to the OkuStim, a neuro-
stimulation device manufactured by Okuvision GmbH. 
Individual phosphene threshold was established using 
the OkuStim software (V.1.4.4.0). Stimulation parame-
ters included pulses of 5 ms positive deflection and 5 
ms negative deflection with a frequency of 20 Hz. The 
current delivered was slowly titrated up from 0.02 mA, 
in increments of 0.01–0.05 mA to a maximum current 
of 1.0 mA, until participants perceived phosphenes. 
This phosphene threshold was then rechecked a further 
two times using a staircase method. The average of the 
three values formed the participant’s individual phos-
phene threshold (IPT). The IPT was recorded onto 
the participant’s unique USB stick, which was attached 
to the base of the OkuStim. The current of TES deliv-
ered was 150% of the IPT. If phosphenes could not be 
elicited during threshold determination or the partic-
ipant’s IPT exceeded 0.66 mA, a treatment current of 
1.0 mA was used. Generally, the subjectively worse eye, 
as perceived by the participant, was chosen for TES with 
an exception in participant 12 001 as MP could not be 
conducted consistently in the worse seeing eye.
statistical analysis
Goldmann visual fields were digitised using the Plot 
Digitizer V. 2.6.4 (Joseph Huwaldt and Scott Steinhorst, 
Massachusetts, USA). These allowed volumetric anal-
ysis of the fields using the V4e, III4e and I4e isopters 
to be conducted in an excel spreadsheet.18 FME (Safe 
Software, Ontario, Canada) converted the plots into a 
three-dimensional visual representation of the fields 
(see online supplementary figure 2). Regarding AF, 
the hyperfluorescent ring, characteristic of RP, was 
analysed according to a method previously described.19 
Briefly, the hyperfluorescent ring was captured using a 
percentile grading system and the radius relative to the 
fovea was recorded over all time points. Assessments 
were split between the treatment period (baseline and 
6 months) and observation period (between 6 and 12 
months). The two periods were then compared using 
Wilcoxon signed rank tests due to non-normality of 
the data. All statistical analysis was conducted with 
SPSS V.22.0 (IBM, Chicago, Illinois, USA). Results are 
presented as mean±SEM.
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Table 2 A list of all AEs encountered during the study
AE number AE Relationship to device Severity Resolution
001 FB sensation Yes Mild 24 hours
002 Supraorbital ache Unlikely Mild 1 month
003 FB sensation Yes Mild 24 hours
004 Herpes zoster ophthalmicus Unlikely (contralateral) Moderate 1 month
005 Skin electrode discomfort Yes Mild Immediate
006 Skin electrode discomfort Yes Mild Immediate
One participant experienced supraorbital ache, although this was with concurrent sinusitis and was not in the location of the skin electrode. 
One case of herpes zoster ophthalmicus was considered unrelated and affected the contralateral side.
AE, adverse effect; FB, foreign body.
Table 3 Mean data for all participants at baseline, after 6 months of TES and and at 12 months
Parameter Baseline 6 months (treatment period) 12 months (observation period)









































C, control eye; OCT, optical coherence tomography; sr, steradians; T, treated eye.
results
Fourteen participants, aged 18–79 years, with clini-
cally confirmed RP were recruited into an open-label 
observational trial from both Oxford Eye Hospital 
and Moorfields Eye Hospital. Seven participants had 
recognised mutational variants associated with RP. 
Participant demographics are illustrated in table 1. All 
14 participants completed the initial 6-month treatment 
period; however, two participants withdrew during the 
observational period due to personal reasons (figure 1). 
TES was generally well tolerated with no serious adverse 
events (AEs) experienced during the trial supporting 
the primary end point of safety. A catalogue of all AEs is 
listed in table 2. The most frequent AEs were transient 
(<24 hours) self-resolving foreign body (FB) sensation 
experienced in two participants and discomfort under-
neath the skin electrode by one participant on two 
occasions. The latter was rectified by replacement of 
the electrode. The remaining AEs were not deemed to 
have a relationship to TES. One case of herpes zoster 
ophthalmicus, which affected the contralateral side, 
resolved with management by the participant’s primary 
care physician. There was also one case of supraorbital 
ache, although this occurred halfway through the study, 
was not in the location of the skin electrode and was 
associated with concurrent sinusitis. This resolved after 
1 month with no additional treatment. Mean data and 
raw data values of the secondary outcome measures are 
shown in tables 3 and 4 respectively.
Visual acuity
Baseline BCVA was 72.3±5.9 and 71.2±4.8 EDTRS letters 
in the control and treated eye, respectively (n=14). 
Following the treatment period, BCVA increased by 
1.1±1.4 in the control arm and 0.93±1.4 letters in the 
treated arm (P=0.58, n=14). Final BCVA (12 months 
following initiation of TES) relative to baseline decreased 
by 0.5±1.1 and 0.3±1.4 letters in the control and treated 
eyes, respectively (P=0.77, n=12).
Microperimetry
The 10–2 degree MP was carried out in all subjects, 
although participant P1 had poor fixation rendering the 
results unreliable and was therefore excluded from the 
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Table 4 Raw data for all participants at baseline, after 6 months of TES and at 12 months
Participant Visit Baseline 6 Months 12 Months
P1 BCVA (letters) C=88 T=0.650 C=84 T=88 C=86 T=83
GVF (sr) C=1.000 T=88 C=1.059 T=0.816 C=1.407 T=1.075
MP (db) C=25.1 T=24.0 C=25.1 T=25.5 C=25.7 T=23.5
IPT (mA) T=0.3 T=0.35 T=0.3
P2 BCVA (letters) C=59 T=60 C=60 T=58 C=60 T=60
GVF (sr) C=0.099 T=0.101 C=0.139  T=0.131 C=0.136  T=0.138
MP (db) C=3.1 T=2.7 C=3.1  T=3.4 C=6.1 T=3.4
IPT (mA) T =>1.0 T=0.3 T=0.85
P3 BCVA (letters) C=88 T=86 C=79 T=84 C=84 T=85
GVF (sr) C=2.628 T=3.431 C=2.592 T=3.158 C=2.265 T=2.697
MP (db) C=9.0 T=2.8 C=8.5 T=2.7 C=1.8 T=7.0
IPT (mA) T=0.55 T =>1.0 T=0.55
P4 BCVA (letters) C=82 T=80 C=88 T=85 C = * T = *
GVF (sr) C=0.736 T=0.606 C=0.963 T=0.742
MP (db) C=27.5 T=27.0 C=27.0  T=27.7
IPT (mA) T=0.08 T=0.18
P5 BCVA (letters) C=52 T=60 C=56 T=61 C=54 T=62
GVF (sr) C=0.112 T=0.150 C=0.149  T=0.176 C=0.152 T=0.160
MP (db) C=0.7 T=0.5 C=0.4 T=0.9 C=1.7 T=1.1
IPT (mA) T=0.6 T=0.4 T=>1.0
P6 BCVA (letters) C=75 T=76 C=70 T=69 C=73 T=67
GVF (sr) C=0.076 T=0.109 C=0.082 T=0.165 C=0.093 T=0.100
MP (db) C=0.8 T=2.7 C=0.6  T=1.3 C=0.6 T=0.7
IPT (mA) T=0.25 T=0.55 T=0.35
P7 BCVA (letters) C=6 T=53 C=15 T=62 C=14 T=56
GVF (sr) C=0.599 T=0.545 C=0.943 T=0.988 C=1.082 T=0.842
MP (db) Poor fixation Poor fixation Poor fixation
IPT (mA) T=0.58 T=0.80 T=0.85
P8 BCVA (letters) C=68 T=26 C=68 T=30 C = * T = *
GVF (sr) C=0.149 T=0.183 C=0.105 T=0. 208
MP (db) C=4.0 T=4.6 C=6.2 T=7.1
IPT (mA) T=0.09 T=0.37
P9 BCVA (letters) C=81 T=81 C=89 T=80 C=81 T=83
GVF (sr) C=1.600 T=1.963 C=2.330 T=2.963 C=2.188 T=3.288
MP (db) C=10.1 T=13.9 C=9.7 T=16.0 C=7.6 T=15.2
IPT (mA) T=0.32 T=0.38 T=0.42
P10 BCVA (letters) C=88 T=88 C=88 T=89 C=82 T=84
GVF (sr) C=2.877 T=2.402 C=3.585 T=3.272 C=2.892 T=3.399
MP (db) C=18.1 T=17.2 C=18.4 T=17.5 C=17.1 T=16.0
IPT (mA) T=0.22 T=0.19 T=0.13
P11 BCVA (letters) C=77 T=56 C=76 T=70 C=72 T=65
GVF (sr) C=1.118 T=2.558 C=1.723  T=2.458 C=1.557  T=2.684
MP (db) C=15.9 T=16.7 C=17.8 T=16.0 C=16.0 T=14.2
IPT (mA) T=0.45 T=0.30 T=0.32
Continued
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Participant Visit Baseline 6 Months 12 Months
P12 BCVA (letters) C=75 T=72 C=77 T=66 C=72 T=67
GVF (sr) C=2.633 T=1.415 C=2.377 T=2.482 C=1.843 T=1.646
MP (db) C=7.7 T=4.0 C=2.2 T=0.9 C=0.9 T=0.0
IPT (mA) T=0.16 T=0.23 T=0.56
P13 BCVA (letters) C=88 T=84 C=88 T=85 C=89 T=88
GVF (sr) C=1.157 T=1.684 C=0.951  T=1.310 C=1.173 T=1.491
MP (db) C=16.7 T=18.1 C=18.5 T=18.1 C=18.5  T=17.9
IPT (mA) T=0.77 T=0.82 T=0.73
P14 BCVA (letters) C=88 T=87 C=87 T=85 C=89 T=87
GVF (sr) C=0.481 T=0.187 C=0.458 T=0.235 C=0.497 T=0.294
MP (db) C=14.5 T=17.1 C=15.9 T=19.0 C=19.1 T=16.1
IPT (mA) T=0.43 T=0.45 T=0.25
IPT was only conducted on the treated eye.
* =*Not available, participant withdrawn.
BCVA, best-corrected visual acuity; C, control eye; GVF, Goldmann visual fields; IPT, individual phosphene threshold; MP, microperimetry; T, 
treated eye.
Table 4 Continued 
Figure 2 Graph demonstrating the change in central parameters of central retinal thickness (CRT) as measured by optical 
coherence tomography (OCT) and threshold sensitivity of the central 10 degrees using the MAIA microperimeter (MP). There 
was no statistical significance noted between the control eye and treated eye following the treatment period (CRT: P=0.91, MP: 
P=0.68) or the observation period (CRT: P=0.52, MP: P=0.43).  
analysis (figure 2). Baseline MP 10–2 threshold sensitivity 
was 11.8±2.3 dB for the control eye and 11.6±2.4 dB for 
the treated eye (n=13). At the 6-month visit, sensitivity 
increased by 0.02±0.51 and 0.37±0.41 dB in the control 
and treated eye, respectively (P=0.68, n=13). Final visit 
MP, relative to baseline, revealed a decrease of 0.46±0.79 
and 0.56±0.53 dB in the control and treated eyes, respec-
tively (P=0.43, n=11).
Goldmann visual field
GVF analysis, as described earlier, provided a value, 
measured in sr. As the trial cohort consisted of partic-
ipants with a wide spectrum of disease severity, GVF 
showed large variation with a range of 0.09–2.87 sr 
in the control eye and 0.10–3.43 sr in the treated 
eye (figure 3). Baseline GVF was 1.09±0.27 sr in the 
control arm and 1.14±0.29 sr in the treated arm. There 
was a slight increase in GVF after 6 months of TES, 
0.16±0.09 sr vs 0.22±0.12 sr for the control and treated 
eyes, respectively (P=0.58, n=14). At last follow-up, there 
was a non-significant overall increase of 0.07±0.11 sr for 
the control arm and 0.22±0.15 sr for the treated arm 
compared with baseline (P=0.91, n=12).
Optical coherence tomography
Central retinal thickness (CRT) was measured using the 
calliper function in Heidelberg Eye Explorer software 
associated with the camera. On trial recruitment, four 
participants had mild epiretinal membranes without any 
traction or intraretinal fluid. One participant exhibited 
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Figure 3 Graph demonstrating the change in peripheral parameters of mean annular radius using autofluorescence (AF) and 
volume of Goldmann visual field (GVF). There was no statistical significance noted between the control eye and treated eye 
following the treatment period (AF: P=0.16, GVF: P=0.58) or the observation period (AF: P=0.64, MP: P=0.91).
a staphyloma. A thickened posterior hyaloid face was 
noted in two participants. Cystoid macular oedema was 
an excluding factor and was not identified in any partic-
ipant throughout the study duration.
Baseline CRT in the control and treated eye was 200±11 
and 191±13 µm, respectively (n=14). At 6 months, CRT 
reduced marginally to 193±14 and 186±14 µm for the 
control and treated eye, respectively (P=0.91, n=14) with 
further decrease at 12 months to 184±14 in both eyes 
(P=0.52, n=12) (figure 2). Exacerbation of any retinal 
pathology, such as epiretinal membrane, was not noted 
through the study.
Fundus autofluorescence
As with GVF, there was a large spectrum of baseline values 
illustrating the spectrum of disease severity. Mean radius 
of the hyperfluorescent annulus at the initial visit was 
1577±141 µm for the control arm vs 1681±153 µm for the 
treatment arm. At 6 months, the annulus radius increased 
in the control eye by 70±115 µm while in the treated eye, 
it decreased by 12±105 µm (P=0.16, n=14). At 12 months, 
the diameter decreased relative to baseline in both the 
control and treated eye by 34±150 and 268±100 µm, 
respectively (P=0.64, n=12) (figure 3), consistent with 
anatomically progressive disease.
dIscussIOn
The results of this prospective open-label trial achieved 
its primary end point providing further evidence of the 
favourable safety profile of TES. Participants underwent 
6 months of weekly TES and AEs related to the inter-
vention were mostly isolated to mild self-limiting ocular 
surface disease manifesting as foreign body sensation. 
One patient experienced discomfort under the counter 
skin electrode on two separate occasions; however, this 
was quickly rectified by the application of a new electrode. 
There were no serious AEs recorded and no deleterious 
impact on visual function or structural measures was seen. 
All participants completed the initial treatment period. 
Akin to retinal vein occlusion, neurotrophic upregula-
tion has been implicated in RP-associated cystoid macular 
oedema20 21 suggesting a possible risk with TES; however, 
this was not noted through the study.
Electrical stimulation therapy has been reported as 
early as 1873 when Dor described the beneficial impact in 
a case series of patients with conditions ranging from RP 
to amblyopia.22 More recently, renewed interest has come 
from the observation that those undergoing implantation 
of retinal prostheses showed persistent visual improve-
ments in areas distant from the implant.8 9 Animal models 
of retinal degeneration have demonstrated preservation 
of photoreceptor and resulting electroretinography after 
application of TES. The completion of a sham-controlled 
randomised clinical trial in patients with RP undergoing 
weekly TES for period of 6 weeks showed that it was safe 
and also revealed improvements in the scotopic b-wave 
amplitude and kinetic perimetry (a 17% increase in the 
visual field area vs a 6% decrease in the sham-stimulated 
group) of those participants receiving a TES current 
of 150% of the IPT.15 A subsequent follow-up study did 
not reproduce the perimetric improvements seen in the 
pilot study, but did demonstrate gains in the photopic 
ERG function suggesting an impact on the cone photo-
receptor system.16 Our study differed in incorporating 
10-degree MP to evaluate cone function more robustly 
and fundus AF to look at peripheral structure. Stimula-
tion of one eye while the other acted as a control aimed 
to obviate concerns over variable rates of progression 
between different individuals with RP.
On the basis of previous reports, we hypothesised that 
participants with RP might demonstrate an improve-
ment in their kinetic perimetry and possibly 10-degree 
MP. However, in contrast to the pilot study, our results 
showed no detectable difference in the measured efficacy 
outcomes within the protocol of this study. A number of 
group.bmj.com on April 17, 2018 - Published by http://bmjophth.bmj.com/Downloaded from 
8 Wagner SK, et al. BMJ Open Ophth 2017;2:e000096. doi:10.1136/bmjophth-2017-000096
Open Access
reasons can be proposed for this relating to both the 
target disease and the methodology—first RP is slowly 
progressive and the 6-month duration of TES may not 
be a sufficient period to perceive intereye differences. 
This becomes particularly relevant in a novel therapy, 
which is more likely to slow disease progression rather 
than reverse retinal degeneration. Second, although 
inherited retinal dystrophies generally affect both eyes 
equally, rates of progression may be slightly asymmetric 
confounding subsequent analysis. This pertains especially 
to our study where the participant’s subjectively worse 
eye, and therefore possibly the more rapidly progressing 
eye, was chosen due to the primary outcome measure 
of safety. A further caveat emerges when considering 
the phenotypic and genotypic heterogeneity of RP—
regarding the former, patients with the same mutation 
may progress at substantially different rates rendering 
comparison difficult. From a genetic perspective, the 
varied pathophysiological mechanisms through which 
different mutations may ultimately induce rod-cone 
dystrophy might conceivably have different degrees of 
response to TES or indeed neurotrophic upregulation. 
Finally, the possibility of some unwanted signal of TES 
on the control eye, a stimulation crosstalk, can also not 
be excluded.
The stimulation parameters used in the current study 
reflect those in the pilot study, which were found to be 
safe and demonstrated significant improvements in 
kinetic perimetry and scotopic electroretinography. In 
that study, only 150% of the IPT was found to be associ-
ated with improvement but not an increased frequency of 
AEs. IPTs of patients with retinal dystrophies are known 
to exceed those of healthy volunteers with reports that 
the stimulation current required might correlate with the 
visual acuity.23 In our study, those participants in whom 
the IPT exceeded the protocol range generally exhib-
ited the greatest visual field constriction. A frequency of 
20 Hz stems from preclinical work demonstrating that 
this level confers the greatest rescue of retinal ganglion 
cells following optic nerve transection in adult Wistar 
rats.24 25 In regard to electrode choice, several groups 
have used bipolar contact lens electrodes to deliver TES; 
however, the alternative DTL electrode has been shown 
to be non-inferior in eliciting phosphenes and may be 
more comfortable and easier to apply for patients.26 Both 
approaches may be associated with a superficial punctate 
keratitis and resulting foreign-body sensation.
Recently, the advent of molecular therapies including 
gene therapy and stem cell transplantation hold great 
promise for inherited retinal diseases; however, there are 
potential advantages of TES. It is a non-invasive modality 
mitigating concerns associated with surgery such as 
endophthalmitis and retinal detachment as well as gene 
therapy implications of systemic toxicity and oncogen-
esis. It is well tolerated, as seen in our study, and the 
electrodes have nominal cost implications. Finally, the 
stimulation parameter adjustment is relatively simple and 
participants can be trained to deliver TES independently. 
Indeed, after the first few sessions of TES, many partici-
pants in our cohort often opted to prepare and manage 
the device themselves under the guidance of a trained 
researcher.
To more rigorously assess the efficacy of TES, a number 
of amendments could improve subsequent studies. As 
mentioned previously, the insidious progression of RP 
warrants a treatment period of longer duration to conclu-
sively determine whether TES delays progression; ideally 
control participants would demonstrate statistically signif-
icant progression during the study for comparison with 
those undergoing TES. Rather than a single eye under-
going TES, it would be prudent to include randomisation 
and compare sham-stimulated versus TES participants to 
avoid possible stimulation crosstalk. It is also plausible 
that certain mutations may respond more favourably 
than others to TES; genetic sequencing may therefore be 
helpful to identify possible ‘responder’ groups. Notwith-
standing these limitations of our study, we find the robust 
safety profile reported here to justify further evaluations 
of TES.
In conclusion, our findings confirm the long-term 
safety of TES justifying its further assessment. A subse-
quent study evaluating its efficacy in RP would ideally 
have a longer TES treatment period and incorporate 
sham-stimulated participants as a control measure.
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